Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
EFFISAYIL™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in adolescents and adults with generalized pustular psoriasis (GPP) up to 48 weeks.1,2 Safety data were in line with previously conducted clinical trials with spesolimab.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230129005023/en/
“Painful GPP flares can occur suddenly, escalate quickly, and may require urgent hospital care leaving people anxious and uncertain about what the future might hold,” said Carinne Brouillon, Member of the Board of Managing Directors, responsible for Human Pharma, Boehringer Ingelheim. “The EFFISAYIL™ 2 results reinforce the potential of spesolimab to prevent GPP flares, giving patients the power to plan their lives, regardless of their disease. We look forward to presenting the data later this year and sharing the findings with regulatory authorities.”
GPP is a rare skin disease, which is distinct from plaque psoriasis.4 GPP flares greatly affect a person’s quality of life and can lead to serious and life-threatening complications, including heart failure, renal failure, and sepsis.4
Spesolimab (marketed as SPEVIGO®) is currently indicated for the treatment of GPP flares in adults.
Spesolimab is a novel, humanized, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of several autoinflammatory diseases, including GPP.4,6,7 Spesolimab has been approved by regulatory authorities in several countries including the US, Japan, Mainland China and the European Union to treat GPP flares in adults.8,9
It is the first approved treatment to specifically target the IL-36 pathway for the treatment of GPP flares that has been evaluated in a statistically powered, randomized, placebo-controlled trial. Further spesolimab data is expected later this year, including the final EFFISAYIL™ 2 results investigating prevention of GPP flares. Spesolimab is also under investigation for the treatment of other IL-36 mediated skin diseases.10
About the EFFISAYIL ™ clinical trial program
The EFFISAYIL™ clinical trial program includes:
- EFFISAYIL™ 1: Treatment with spesolimab demonstrated rapid pustular and skin clearance in patients with GPP flares, sustained over 12 weeks.3 These results supported the approval of spesolimab (SPEVIGO®) as the first specific treatment for GPP flares in adults in major markets including the US, Japan, Mainland China and the European Union.8,9
- EFFISAYIL™ 2: A multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating the efficacy and safety of maintenance treatment with subcutaneous (SC) spesolimab for the prevention of GPP flares and sustained control of GPP symptoms in adolescents and adults.1,2
- EFFISAYIL™ ON: To evaluate the long-term safety and efficacy of Spesolimab in patients with GPP, who have completed previous Spesolimab trials.5
Results from the EFFISAYIL™ 2 and EFFISAYIL™ ON trials will be presented later this year.
For the full press release including ‘Notes to Editors’ and references please visit: press release
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230129005023/en/
Media + PR
Phone: +49 (6132) 77-173436
Additional information: www.boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Campbell Lutyens and J.P. Morgan announce strategic collaboration in the secondary advisory market21.3.2023 14:30:00 EET | Press release
Campbell Lutyens and J.P. Morgan are pleased to announce the establishment of a strategic collaboration to jointly offer their advisory services on single-asset and concentrated multi-asset continuation fund secondary transactions. The offering will enable clients to benefit from Campbell Lutyens’ and J.P. Morgan’s global, market leading secondary and Investment banking advisory practices, respectively. The proposition combines J.P. Morgan’s global top-tier investment banking services with Campbell Lutyens’ leading global placement and secondary advisory platform, creating a best-in-class global offering for single-asset and concentrated multi-asset continuation funds. It will be available for clients across all regions and sectors in which Campbell Lutyens and J.P. Morgan both operate. The offering provides access to Campbell Lutyens’ secondaries expertise focused on fund structuring and capital raising from secondaries and institutional investors along with J.P. Morgan’s M&A services
KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated Switzerland Facility Five Months After Opening21.3.2023 14:30:00 EET | Press release
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced that late in 2022, it successfully released its inaugural First In Human (FIH) manufacturing batch in compliance with current Good Manufacturing Practice (cGMP) standards in its recently expanded Geneva mammalian cell manufacturing facility. The swift execution of this important milestone demonstrates the capabilities in cell line development (CLD) and biologics manufacturing of KBI and Selexis, allowing clients to accelerate clinical research timelines. In July 2022, KBI and Selexis announced the completion of the fully integrated, 8,733 square-meter site combining Selexis’ Cell Line Development services and KBI’s development and manufacturing services. This milestone comes only five months after starting operations at the combined facility. “Delivering this first batch affirms KBI’s commitment to helping pharmaceutical and biotechnology companies across the world achieve their manufacturing goals,” said Mike Land
Visa Defines New Era of How Money Travels Abroad21.3.2023 14:00:00 EET | Press release
Remittances are not only a lifeline for millions of migrant workers and their families, they are also vitally important for the prosperity of many developing economies around the world. As the amount of global remittance inflows continues to reach new records1, 53% of surveyed consumers are turning to digital apps to send and receive funds around the world. Visa today unveiled its “Money Travels: 2023 Digital Remittances Adoption” research report, a survey of over 14,000 consumers across ten countries, revealing that digital remittances are quickly becoming the most popular way to move money internationally, when compared to going to a physical bank or branch (34%); sending cash, checks or money orders by mail (12%); or giving money to another person who is traveling to their home country (11%). In conjunction with the study, Visa launched “Money Travels,” a new podcast series unearthing how payment-related topics unfold differently in various places around the world and highlighting t
Hansen Powers Intraday Trading for Skellefteå Kraft21.3.2023 12:00:00 EET | Press release
Hansen Technologies (ASX:HSN), a leading global provider of software and services to the energy, water and communications industries, is pleased to announce a new agreement with Skellefteå Kraft, an energy company operating in Sweden. As part of the agreement, Skellefteå Kraft, will use Hansen Trade for automated intraday trading operations. The intraday trading solution within Hansen Trade will enable Skellefteå Kraft to automate intraday trading operations and reach significant cost savings in balance management. Skellefteå Kraft will thus be able to automate intraday trading operations with a modern and easy-to-use trading solution – thereby allowing the company to produce beneficial outcomes and implement zero-touch automation. This in turn will replace costly, manual interventions, and minimise risks in the real-time intraday market. Stefan Forsgren, Business Area Director, Power System at Skellefteå Kraft commented: “In the current volatile climate, which also encompasses the rap
REPLY: Comwrap Reply Named Adobe 2023 Digital Experience Emerging Partner of the Year - Central Europe21.3.2023 11:30:00 EET | Press release
Comwrap Reply, the Reply Group company that specialises in cloud-native digital experience services has been awarded the prestigious Adobe 2023 Digital Experience Emerging Partner of the Year - Central Europe. The award honours companies that have made leading contributions to Adobe’s business and significantly impacted customer success. This award is the result of a strategic roadmap that started with Adobe in 2008 to provide high-value solutions to customers and organisations throughout the world. This announcement comes after Reply acquired multiple Adobe Specializations in recent years and was named a Platinum Solution Partner in 2022. “Comwrap Reply demonstrated strong collaboration with Adobe Customer Solutions by delivering cloud-native client implementations. They have proven their continued dedication toward growing their Adobe Experience Platform practice in Europe, which contributed significantly to earning this award. We look forward to continuing our strategic partnership
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom